Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 4/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | PRKCI | P41743 | 5/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | CIT | O14578 | 3/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4874273 | 0.90 | NUDT1 (0.43) | NUDT1MAPK14PRKCICITJAK2 | |
| SCHEMBL4872929 | 0.74 | DCTPP1 (0.35) | DCTPP1 | |
| SCHEMBL12127928 | 0.67 | IKBKB (0.63) | NUDT1PRKCIPIK3C3CITJAK2 | |
| SCHEMBL858198 | 0.66 | AURKB (0.57) | NUDT1PRKCIJAK2CCNKCDK12 | |
| SCHEMBL29946359 | 0.66 | AURKB (0.57) | NUDT1PRKCIJAK2CCNKCDK12 | |
| SCHEMBL4876533 | 0.66 | MAPT (0.33) | — | |
| SCHEMBL12127486 | 0.64 | IGF1R (0.55) | NUDT1MAPK14PRKCIJAK2CCNK | |
| SCHEMBL3576055 | 0.63 | CIT (0.53) | NUDT1PRKCIPIK3C3CITJAK2 | |
| SCHEMBL4869275 | 0.62 | CCNK (0.44) | MAPK14PRKCICITJAK2CCNK | |
| SCHEMBL17594319 | 0.62 | WNT1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PDE5A, PDE3B, PDE12 | NUDT1 1125/4885MAPK14 2249/4885PRKCI 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.